{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:31:53Z","timestamp":1740173513443,"version":"3.37.3"},"reference-count":49,"publisher":"Endocrinology Research Centre","issue":"2","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p><jats:bold>BACKGROUND<\/jats:bold>: Hyperthyreoidism due to Graves\u2019 disease is a rare disorder in pediatric practice. There is 2 treatment options in Graves\u2019 disease: medical treatment and definitive treatment, including surgery and radioactive iodine. Each method has its advantages and disadvantages. If medical therapy is ineffective the choice between radical treatment method is raised: radioactive iodine or total thyroidectomy. In this research we analyze treatment outcomes in pediatric Graves\u2019 disease patients after different radical treatment methods.<\/jats:p><jats:p><jats:bold>AIM<\/jats:bold>:\u00a0Comparative analysis of radical treatment outcomes in pediatric patients with Graves\u2019 disease.<\/jats:p><jats:p><jats:bold>MATERIALS AND METHODS<\/jats:bold>:\u00a0Retrospective and prospective one-center research of 122 patients with Graves\u2019 disease after radical treatment (between 2016 and 2021)<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold>:\u00a0The mean age was 13.5\u00b13,5 year at the moment of examination. Patients were divided into 2 groups due to the radical treatments method: 1 group (n=60) were children after surgical treatment, 2 group (n=62) \u2014 after radioactive iodine. The mean dose of medical treatment in these groups did not reliably differ (p=0,06), duration of the medical treatment was reliably longer in patients after radioactive iodine (p=0,024). Graves\u2019 orbitopathy was diagnosed in 58 patients (47,5%) and met equally often in both groups, but active stage of Graves\u2019 orbitopathy was diagnosed only in patients from the 1st\u00a0group. Thyroid size was reliable bigger in patients from the 1st\u00a0group (p=0,004), and thyroid gland nodes were diagnosed only in patients from 1st\u00a0group (p=0,0007).<\/jats:p><jats:p><jats:bold>CONCLUSION<\/jats:bold>:\u00a0RI can be considered an effective and safe treatment for GD. The effectiveness of RI depends on the volume of the thyroid gland; according to the results of the constructed ROC curve, the risk of repeated RI is higher with a volume of more than 55 cm3. Also radioactive iodine is undesirable if there is signs of ophatalmopathy due to its possible deterioration. According to the results of the study hypoparathyroidism after surgical treatment was diagnosed in 20%, recurrent laryngeal nerve injury was diagnosed after surgical treatment in 5% of patients. In patients with identified nodular goiter according to the results of ultrasound, surgical treatment is preferable due to the impossibility of excluding thyroid cancer.<\/jats:p>","DOI":"10.14341\/probl13086","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T08:23:05Z","timestamp":1651306985000},"page":"104-111","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":0,"title":["Definitive treatment of Graves\u2019 disease in children"],"prefix":"10.14341","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4541-7673","authenticated-orcid":true,"given":"T. E.","family":"Ivannikova","sequence":"first","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2604-1703","authenticated-orcid":true,"given":"T. Yu.","family":"Shiryaeva","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6429-7198","authenticated-orcid":true,"given":"E. V.","family":"Nagaeva","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3785-0335","authenticated-orcid":true,"given":"M. S.","family":"Sheremeta","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3734-6510","authenticated-orcid":true,"given":"D. N.","family":"Brovin","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9621-5732","authenticated-orcid":true,"given":"O. B.","family":"Bezlepkina","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Abraham-Nordling M, Bystr\u00f6m K, T\u00f6rring O, et al. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol. 2011;165(6):899-905. doi: https:\/\/doi.org\/10.1530\/EJE-11-0548","DOI":"10.1530\/EJE-11-0548"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Simon M, Rigou A, Le Moal J, et al. Epidemiology of Childhood Hyperthyroidism in France: A Nationwide Population-Based Study. J Clin Endocrinol Metab. 2018;103(8):2980-2987. doi: https:\/\/doi.org\/10.1210\/jc.2018-00273","DOI":"10.1210\/jc.2018-00273"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland. Clin Endocrinol (Oxf). 2010;72(3):358-363. doi: https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03717.x","DOI":"10.1111\/j.1365-2265.2009.03717.x"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Kaguelidou F, Alberti C, Castanet M, et al. Predictors of Autoimmune Hyperthyroidism Relapse in Children after Discontinuation of Antithyroid Drug Treatment. J Clin Endocrinol Metab. 2008;93(10):3817-3826. doi: https:\/\/doi.org\/10.1210\/jc.2008-0842","DOI":"10.1210\/jc.2008-0842"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Wong GWK, Cheng PS. Increasing incidence of childhood Graves\u2019 disease in Hong Kong: A follow-up study. Clin Endocrinol (Oxf). 2001;54(4):547-550. doi: https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01252.x","DOI":"10.1046\/j.1365-2265.2001.01252.x"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Rodanaki M, Lodefalk M, Forssell K, et al. The Incidence of Childhood Thyrotoxicosis Is Increasing in Both Girls and Boys in Sweden. Horm Res Paediatr. 2019;91(3):195-202. doi: https:\/\/doi.org\/10.1159\/000500265","DOI":"10.1159\/000500265"},{"key":"ref7","unstructured":"Federal\u2019nye klinicheskie rekomendatsii (protokoly) po vedeniyu detei s endokrinnymi zabolevaniyami. Ed by Dedov II, Peterkova VA. \u2014 Moscow: Praktika; 2014. P. 215-239. (In Russ.)."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"\u0411Bezlepkina OB. Federal clinical recommendations on diagnostics and treatment of Graves\u2019 disease in the children. Problems of Endocrinology. 2014;60(3):59-68. (In Russ.). doi: https:\/\/doi.org\/10.14341\/probl201460359-68","DOI":"10.14341\/probl201460359-68"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"van Lieshout JM, Mooij CF, van Trotsenburg ASP, Zwaveling-Soonawala N. Methimazole-induced remission rates in pediatric Graves\u2019 disease: a systematic review. Eur J Endocrinol. 2021;185(2):219-229. doi: https:\/\/doi.org\/10.1530\/EJE-21-0077","DOI":"10.1530\/EJE-21-0077"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Kaguelidou F, Alberti C, Castanet M, et al. Predictors of Autoimmune Hyperthyroidism Relapse in Children after Discontinuation of Antithyroid Drug Treatment. J Clin Endocrinol Metab. 2008;93(10):3817-3826. doi: https:\/\/doi.org\/10.1210\/jc.2008-0842","DOI":"10.1210\/jc.2008-0842"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"L\u00e9ger J, Gelwane G, Kaguelidou F, et al. Positive Impact of Long-Term Antithyroid Drug Treatment on the Outcome of Children with Graves\u2019 Disease: National Long-Term Cohort Study. J Clin Endocrinol Metab. 2012;97(1):110-119. doi: https:\/\/doi.org\/10.1210\/jc.2011-1944","DOI":"10.1210\/jc.2011-1944"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Gostimskii AV, Peredereev SS. Sovremennye problemy khirurgicheskogo lecheniya bol\u2019nykh diffuznym toksicheskim zobom detskogo vozrasta. Pediatr. 2013;4:69-76. (In Russ.).","DOI":"10.26442\/CS45511"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Rumiantsev PO, Kiyaev AV, Sehemeta MS, Chikulaeva OA. Radioiodine therapy of thyrotoxicosis in children and adolescents. Indications, efficacy and safety. Literature review. Endocrine Surgery. 2016;10(4):6-12. (In Russ.). doi: https:\/\/doi.org\/10.14341\/serg201646-12","DOI":"10.14341\/serg201646-12"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Bahn RS. Graves\u2019 Ophthalmopathy. N Engl J Med. 2010;362(8):726-738. doi: https:\/\/doi.org\/10.1056\/NEJMra0905750;","DOI":"10.1056\/NEJMra0905750"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Prasai A, Nix PA, Aye M, et al. Total thyroidectomy for safe and definitive management of Graves\u2019 disease. J Laryngol Otol. 2013;127(7):681-684. doi: https:\/\/doi.org\/10.1017\/S0022215113001254","DOI":"10.1017\/S0022215113001254"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Qu\u00e9rat C, Germain N, Dumollard J-M, et al. Surgical management of hyperthyroidism. Eur Ann Otorhinolaryngol Head Neck Dis. 2015;132(2):63-66. doi: https:\/\/doi.org\/10.1016\/j.anorl.2014.04.005","DOI":"10.1016\/j.anorl.2014.04.005"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Edafe O, Antakia R, Laskar N, et al. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. Br J Surg. 2014;101(4):307-320. doi: https:\/\/doi.org\/10.1002\/bjs.9384","DOI":"10.1002\/bjs.9384"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Burch HB, Cooper DS. Management of Graves Disease. JAMA. 2015;314(23):2544-2554. doi: https:\/\/doi.org\/10.1001\/jama.2015.16535","DOI":"10.1001\/jama.2015.16535"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Genovese BM, Noureldine SI, Gleeson EM, et al. What Is the Best Definitive Treatment for Graves\u2019 Disease? A Systematic Review of the Existing Literature. Ann Surg Oncol. 2013;20(2):660-667. doi: https:\/\/doi.org\/10.1245\/s10434-012-2606-x","DOI":"10.1245\/s10434-012-2606-x"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Brito JP, Schilz S, Singh Ospina N, et al. Antithyroid Drugs\u2014The Most Common Treatment for Graves\u2019 Disease in the United States: A Nationwide Population-Based Study. Thyroid. 2016;26(8):1144-1145. doi: https:\/\/doi.org\/10.1089\/thy.2016.0222","DOI":"10.1089\/thy.2016.0222"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Aung ET, Zammitt NN, Dover AR, et al. Predicting outcomes and complications following radioiodine therapy in Graves\u2019 thyrotoxicosis. Clin Endocrinol (Oxf). 2019;90(1):192-199. doi: https:\/\/doi.org\/10.1111\/cen.13873","DOI":"10.1111\/cen.13873"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Sirianong N, Kevalee U, Prapai D, et al. Radioactive Iodine for Thyrotoxicosis in Childhood and Adolescence: Treatment and Outcomes. J Clin Res Pediatr Endocrinol. 2013;5(2):95-97. doi: https:\/\/doi.org\/10.4274\/Jcrpe.951","DOI":"10.4274\/Jcrpe.951"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Azizi F, Amouzegar A. Management of thyrotoxicosis in children and adolescents: 35 years\u2019 experience in 304 patients. J Pediatr Endocrinol Metab. 2018;31(2):159-165. doi: https:\/\/doi.org\/10.1515\/jpem-2017-0394","DOI":"10.1515\/jpem-2017-0394"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Allahabadia A, Daykin J, Sheppard MC, et al. Radioiodine Treatment of Hyperthyroidism\u2014Prognostic Factors for Outcome. J Clin Endocrinol Metab. 2001;86(8):3611-3617. doi: https:\/\/doi.org\/10.1210\/jcem.86.8.7781","DOI":"10.1210\/jcem.86.8.7781"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Prasai A, Nix PA, Aye M, et al. Total thyroidectomy for safe and definitive management of Graves\u2019 disease. J Laryngol Otol. 2013;127:681-684. doi: https:\/\/doi.org\/10.1017\/S0022215113001254","DOI":"10.1017\/S0022215113001254"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Qu\u00e9rat C, Germain N, Dumollard J-M, et al. Surgical management of hyperthyroidism. Eur Ann Otorhinolaryngol Head Neck Dis. 2015;132(2):63-66. doi: https:\/\/doi.org\/10.1016\/j.anorl.2014.04.005","DOI":"10.1016\/j.anorl.2014.04.005"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Phitayakorn R, Morales-Garcia D, Wanderer J, et al. Surgery for Graves\u2019 disease: a 25-year perspective. Am J Surg. 2013;206(5):669-673. doi: https:\/\/doi.org\/10.1016\/j.amjsurg.2013.07.005","DOI":"10.1016\/j.amjsurg.2013.07.005"},{"key":"ref28","unstructured":"Catania A, Guaitoli E, Carbotta G, et al. Total thyroidectomy for Graves\u2019 disease treatment. Clin Ter. 2013;164:193-196. doi: https:\/\/doi.org\/10.7417\/CT.2013.1548"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Genovese BM, Noureldine SI, Gleeson EM, et al. What Is the Best Definitive Treatment for Graves\u2019 Disease? A Systematic Review of the Existing Literature. Ann Surg Oncol. 2013;20(2):660-667. doi: https:\/\/doi.org\/10.1245\/s10434-012-2606-x","DOI":"10.1245\/s10434-012-2606-x"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Liu ZW, Masterson L, Fish B, Jani P, Chatterjee K. Thyroid surgery for Graves\u2019 disease and Graves\u2019 ophthalmopathy. Cochrane Database Syst Rev. 2015. doi: https:\/\/doi.org\/10.1002\/14651858.CD010576.pub2","DOI":"10.1002\/14651858.CD010576.pub2"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Burch HB, Cooper DS. Management of Graves Disease. JAMA. 2015;314(23):2544-2554. doi: https:\/\/doi.org\/10.1001\/jama.2015.16535","DOI":"10.1001\/jama.2015.16535"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Edafe O, Antakia R, Laskar N, et al. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. Br J Surg. 2014;101(4):307-320. doi: https:\/\/doi.org\/10.1002\/bjs.9384","DOI":"10.1002\/bjs.9384"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Oltmann SC, Brekke AV, Schneider DF, et al. Preventing Postoperative Hypocalcemia in Patients with Graves Disease: A Prospective Study. Ann Surg Oncol. 2015;22(3):952-958. doi: https:\/\/doi.org\/10.1245\/s10434-014-4077-8","DOI":"10.1245\/s10434-014-4077-8"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Bellantone R, Lombardi CP, Bossola M, et al. Total thyroidectomy for management of benign thyroid disease: Review of 526 cases. World J Surg. 2002;26(12):1468-1471. doi: https:\/\/doi.org\/10.1007\/s00268-002-6426-1","DOI":"10.1007\/s00268-002-6426-1"},{"key":"ref35","unstructured":"Efremidou EI, Papageorgiou MS, Liratzopoulos N, Manolas KJ. The efficacy and safety of total thyroidectomy in the management of benign thyroid disease: a review of 932 cases. Can J Surg. 2009;52(1):39-44."},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Desforges JF, Mazzaferri EL. Management of a Solitary Thyroid Nodule. N Engl J Med. 1993;328(8):553-559. doi: https:\/\/doi.org\/10.1056\/NEJM199302253280807","DOI":"10.1056\/NEJM199302253280807"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Tufano RP, Noureldine SI, Angelos P. Incidental Thyroid Nodules and Thyroid Cancer. JAMA Otolaryngol Neck Surg. 2015;141(6):566. doi: https:\/\/doi.org\/10.1001\/jamaoto.2015.0647","DOI":"10.1001\/jamaoto.2015.0647"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Wei S, Baloch ZW, LiVolsi VA. Thyroid Carcinoma in Patients with Graves\u2019 Disease: an Institutional Experience. Endocr Pathol. 2015;26(1):48-53. doi: https:\/\/doi.org\/10.1007\/s12022-014-9343-6","DOI":"10.1007\/s12022-014-9343-6"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2016;12(11):646-653. doi: https:\/\/doi.org\/10.1038\/nrendo.2016.110","DOI":"10.1038\/nrendo.2016.110"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"McLeod DSA, Watters KF, Carpenter AD, et al. Thyrotropin and Thyroid Cancer Diagnosis: A Systematic Review and Dose-Response Meta-Analysis. J Clin Endocrinol Metab. 2012;97(8):2682-2692. doi: https:\/\/doi.org\/10.1210\/jc.2012-1083","DOI":"10.1210\/jc.2012-1083"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Boostrom S, Richards ML. Total thyroidectomy is the preferred treatment for patients with Graves\u2019 disease and a thyroid nodule. Otolaryngol Neck Surg. 2007;136(2):278-281. doi: https:\/\/doi.org\/10.1016\/j.otohns.2006.09.011","DOI":"10.1016\/j.otohns.2006.09.011"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Rinaldi S, Plummer M, Biessy C, et al. Thyroid-Stimulating Hormone, Thyroglobulin, and Thyroid Hormones and Risk of Differentiated Thyroid Carcinoma: The EPIC Study. JNCI J Natl Cancer Inst. 2014;106(6). doi: https:\/\/doi.org\/10.1093\/jnci\/dju097","DOI":"10.1093\/jnci\/dju097"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Huang H, Rusiecki J, Zhao N, et al. Thyroid-Stimulating Hormone, Thyroid Hormones, and Risk of Papillary Thyroid Cancer: A Nested Case\u2013Control Study. Cancer Epidemiol Biomarkers Prev. 2017;26(8):1209-1218. doi: https:\/\/doi.org\/10.1158\/1055-9965.EPI-16-0845","DOI":"10.1158\/1055-9965.EPI-16-0845"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Dal Maso L, Bosetti C, La Vecchia C, Franceschi S. Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control. 2009;20(1):75-86. doi: https:\/\/doi.org\/10.1007\/s10552-008-9219-5","DOI":"10.1007\/s10552-008-9219-5"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Shaha AR. Controversies in the Management of Thyroid Nodule. Laryngoscope. 2000;110(2):183-183. doi: https:\/\/doi.org\/10.1097\/00005537-200002010-00001","DOI":"10.1097\/00005537-200002010-00001"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Becker D V. Choice of Therapy for Graves\u2019 Hyperthyroidism. N Engl J Med. 1984;311(7):464-466. doi: https:\/\/doi.org\/10.1056\/NEJM198408163110710","DOI":"10.1056\/NEJM198408163110710"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Kung AW, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves\u2019 disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab. 1994;79(2):542-546. doi: https:\/\/doi.org\/10.1210\/jcem.79.2.7913934","DOI":"10.1210\/jcem.79.2.7913934"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves\u2019 ophthalmopathy. N Engl J Med. 1998;338:73-78. doi: https:\/\/doi.org\/10.1056\/NEJM199801083380201","DOI":"10.1056\/NEJM199801083380201"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Rivkees SA, Dinauer C. An Optimal Treatment for Pediatric Graves\u2019 Disease Is Radioiodine. J Clin Endocrinol Metab. 2007;92(3):797-800. doi: https:\/\/doi.org\/10.1210\/jc.2006-1239","DOI":"10.1210\/jc.2006-1239"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13086\/10251","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T14:13:27Z","timestamp":1651328007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,4,30]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13086","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"type":"electronic","value":"2308-1430"},{"type":"print","value":"0375-9660"}],"subject":[],"published":{"date-parts":[[2022,4,11]]}}}